Valsartan mess to spawn the latest surge of drug injury lawsuits: Bloomberg

lawsuit and book
One attorney predicted plaintiffs will file thousands of lawsuits over valsartan impurities. (Getty/eccolo74)

As the FDA and other drug agencies work to limit damage from a massive recall of blood pressure drugs, litigation stemming from the mess is just getting started.

Lawsuits have started to pile up alleging that tainted versions of valsartan harmed patients. But one lawyer involved says he expects thousands of personal injury lawsuits over the impurities—which turned up in versions of valsartan and its rival meds irbesartan and losartan—in the next two years.

At a status conference last month, attorney Daniel Nigh told judges he expects some 2,000 lawsuits claiming injuries from the adulterated drugs, all within the next two years, Bloomberg reports. So far, since the FDA initiated the first valsartan recall last year, plaintiffs have filed dozens of suits, the news service reports.

The sartan drug fiasco began last year when a U.S. drug manufacturer told the FDA it had discovered the impurity N-nitrosodimethylamine (NDMA) in a valsartan active pharmaceutical ingredient made by China’s Zhejiang Huahai Pharmaceutical. After investigating, the agency found NDMA and a similar chemical, NDEA, had contaminated certain valsartan APIs for years. The agency said the two contaminants, both considered probable carcinogens, can form through a specific and commonly used manufacturing process. 

The findings set off recalls around the world for blood pressure meds valsartan, irbesartan and losartan. The FDA kicked off a probe into the cause of the regulatory slip-up and its associated dangers to consumers. 

In January, the FDA said "overall, the risk to individual patients remains very small," but acknowledged it was still concerned about the episode.

Free Daily Newsletter

Like this story? Subscribe to FiercePharma!

Biopharma is a fast-growing world where big ideas come along daily. Our subscribers rely on FiercePharma as their must-read source for the latest news, analysis and data on drugs and the companies that make them. Sign up today to get pharma news and updates delivered to your inbox and read on the go.

So far, plaintiffs have sued 40 companies, alleging they were harmed by the tainted drugs, Bloomberg reports. Defendants include Zhejiang, generics giants Teva and Mylan and numerous India-based generic drug makers.

In a letter to the judge overseeing the litigation, defense attorneys wrote that NDMA and NDEA are “organic chemicals that are the by-product of several biological and industrial processes.” They appear in air, water, soil, beer, cheese and other substances, the attorneys say, and don’t harm patients if they appear in drugs at trace levels.  

The defendants contend there’s “no evidence that the trace amount” of NDMA and NDEA found in drugs can cause cancer.

Suggested Articles

WuXi Biologics says it will build a dedicated facility to manufacture a commercial vaccine product for a client in a $3 billion contract.

Merck & Co.'s Fosamax fight has lasted for years—and now, thanks to a U.S. Supreme Court ruling Monday, Merck gets yet another chance to press its…

Mallinckrodt’s Acthar Gel has seen its share of lawsuits, but the company was happy to launch another—this time to defend its Medicaid business.